Cumberland Pharma shares slide on regulatory delay; Roche buying BioImagene for $100M;

 @FierceBiotech: U.S. biotech faces fierce international competition. Report | Follow @FierceBiotech

> Shares of Cumberland Pharmaceuticals took a hit after the FDA informed the biotech that it was extending its review of an experimental therapy for acute liver failure--Acetadote--by three months. CPIX stock slid 10 percent on the news that a final decision would have to wait until December. Story

> Solidifying its commitment to diagnostics, Roche announced a deal to buy BioImagene for $100 million. The pharma giant has staked out a big role for advanced diagnostics in creating a new generation of personalized therapies. Report

> Torbjorn Bjerke has been appointed as new CEO for Karolinska Development. He is currently CEO for Orexo, a position he has held since 2007. Torbjorn Bjerke succeeds Conny Bogentoft who will assume the position as Chief Scientific Officer for Karolinska Development. Karolinska release

> Eli Lilly says that it is shuttering a manufacturing facility for Erbitux at the ImClone Systems campus. Story

And Finally... Institute of Food Research scientists are developing new fats that are digested more slowly, spurring a sense of satiety that can promote weight loss. IFR release

Suggested Articles

After seeing later stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight.

T-knife has raised €66 million ($78 million) to take four prospects from its TCR-T-cell platform into the clinic in solid tumor indications.

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.